Renal Impairment: How Does It Affect Angioplasty and Surgery?

Courtesy of Dr. Carlos Fava.
The incidence of kidney disease is increasing. In its final stage, this pathology is related with coronary disease and increased mortality. Furthermore, we know that, in many occasions, it is associated with diabetes.

Deterioro de la función renal: ¿Cómo impacta en la ATC y en la CRM?Nowadays, the evidence comparing the progress of patients with impaired kidney function who have undergone left main coronary angioplasty and those who have undergone myocardial revascularization surgery is insufficient.

 

This is a substudy within the SYNTAX trial that analyzed kidney function as measured by glomerular filtration rate estimates (eGFR). Stage 1 was defined as eGFR ≥90 mL/min per 1.73 m2 (normal renal function [NRF]); stage 2, impaired renal function (IRF), with an eGFR between 60 and 89 mL/min per 1.73 m2; and stages 3 to 5, chronic kidney disease (CKD): stage 3 as eGFR 30-59 mL/min per 1.73 m2, stage 4 as eGFR 15-29 mL/min per 1.73 m2, and stage 5 as chronic dialysis treatment.


Read also: EuroPCR 2018 | RADIANCE-HTN SOLO: Renal Denervation Guided Through Intravascular Ultrasound.


Among 1638 randomized patients, 25.7% of those who underwent angioplasty and 26.6% of those who underwent surgery had normal kidney function. Impaired renal function (stage 2) accounted for 55.8% of patients in the angioplasty group vs. 54.2% of patients in the surgery group. Finally, chronic kidney disease was experienced by 18.5% of patients in the angioplasty group vs. 19.2% in the surgery group (stage 3: 89.9% vs. 90.2%; stage 4: 8.2% vs. 7.3%; stage 5: 1.9% vs. 2%).

 

Patients with CKD had a higher EuroSCORE compared with patients with NRF and IRF, and a higher SYNTAX score (32.2 ± 12.1 vs. 28.2 ± 11.7; p = 0.008).

 

Off-pump surgery was more frequent among patients with CKD (22.1% vs. 13.1% vs. 15.8%, respectively; p = 0.035), and the use of multiple arterial grafts was lower among this group. No differences were observed regarding the number of anastomoses and the completeness of revascularisation.


Read also: EuroPCR 2018 | SPYRAL HTN-ON MED: Renal Denervation Comes Back to Life.


There was no difference regarding the number of stents among patients who underwent angioplasty. However, the rate of complete revascularisation was lower in patients with CKD (46.2% vs 60.5%, vs. 56.5%, respectively; p = 0.007).

 

Aspirin was prescribed less often in patients with CKD; no differences were observed regarding statins and beta-blockers.

 

The incidence of major adverse cardiac or cerebrovascular events (MACCE) at 30 days was similar. No differences were observed in relation with kidney function.


Read also: Contrast Induced Kidney Injury, Infamous Problem with No Magical Solutions.


At 5 years, the rate of MACCE was higher among patients with CKD in the global population, being higher after angioplasty compared with surgery (42.1% vs. 31.5%; p = 0.019). The need for repeat revascularization was lower among patients with NRF.

 

In patients with CKD who also had diabetes, those who underwent surgery had better outcomes that patients in the angioplasty group in terms of the composite death/stroke/infarction, as well as all-cause death.

 

Conclusion
During a 5-year follow-up, event rates were comparable between angioplasty and surgery patients with IRF, but higher in patients with CKD compared to patients with NRF. The long-term negative impact of CKD in patients who undergo angioplasty is higher when compared with those who undergo surgery, particularly among patients with diabetes and extensive coronary disease.

 

Courtesy of Dr. Carlos Fava.

 

Original title: The Impact of Chronic Kidney Disease on Outcomes Following Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting in Patients with Complex Coronary Artery Disease: Five-Year Follow-Up of the SYNTAX Trial.
Reference: Milan Milojevic et al. EuroIntervention 2018;14:102-111.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

ACVC 2026 | FLASH Registry European Cohort: Mechanical Thrombectomy in Pulmonary Embolism

The management of intermediate-high and high-risk pulmonary embolism (PE) remains an area of therapeutic uncertainty, particularly in patients with right ventricular (RV) dysfunction, in...

AHA/ACC Guideline on the Management of Acute Pulmonary Embolism 2026

The 2026 ACC/AHA guideline for the management of acute pulmonary embolism (PE) introduces a conceptual shift by replacing the traditional “risk-based” classification with an...

FFR Assessment for the Selection of Hypertensive Patients Who Benefit from Renal Stenting

Atherosclerotic renal artery stenosis (ARAS) represents one of the main causes of secondary hypertension (HTN) and is associated with a higher risk of renal...

Transcatheter Deep Vein Arterialization in Critical Limb Ischemia Without Revascularization Options

Chronic limb-threatening ischemia in patients without conventional revascularization options represents one of the most challenging scenarios within peripheral arterial disease, with 1-year major amputation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACVC 2026 | CELEBRATE Trial: Prehospital Zalunfiban Use in STEMI

Optimizing antithrombotic therapy in the prehospital phase of ST-segment elevation myocardial infarction (STEMI) remains challenging due to the delayed onset of action of P2Y12...

ACVC 2026 | BOX Substudy: Mean Arterial Pressure Targets in Cardiogenic Shock After OHCA

Hemodynamic management of cardiogenic shock following ischemic out-of-hospital cardiac arrest (OHCA-AMICS) remains an unresolved issue, particularly regarding optimal mean arterial pressure (MAP) targets and...

ACVC 2026 | FLASH Registry European Cohort: Mechanical Thrombectomy in Pulmonary Embolism

The management of intermediate-high and high-risk pulmonary embolism (PE) remains an area of therapeutic uncertainty, particularly in patients with right ventricular (RV) dysfunction, in...